Sign in

CIK 0001737953 · Non-accelerated filer<br>Smaller reporting company

Replimune Group, Inc.

Sign in to watch
Ticker
REPL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Mar 31
Incorporated
DE
Entity type
operating
EIN
822082553
Phone
(781) 222-9600
Business address
500 UNICORN PARK, WOBURN, MA, 01801
  1. 4 Derivatives Options or other derivatives
  2. 4 Grant or award Chief Medical Officer acquired 26,665 shares (grant or award)
  3. 4 Derivatives Options or other derivatives
  4. 4 Grant or award Chief Financial Officer acquired 26,665 shares (grant or award)
  5. 4 Grant or award Chief Commercial Officer acquired 22,225 shares (grant or award)
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Grant or award Chief Accounting Officer acquired 17,775 shares (grant or award)
  11. 4 Open-market sale Chief Medical Officer sold 7,313 shares at $10.92 ($79,858)
  12. 4 Open-market sale Chief Commercial Officer sold 5,255 shares at $10.92 ($57,385)
  13. 4 Grant or award Chief Financial Officer acquired 83,330 shares (grant or award)
  14. 3 Insider Initial Statement of Ownership
  15. 4 Planned sale Chief Business Officer sold 5,658 shares at an average $20.01 ($113,214)
  16. 4 Planned sale Chief Business Officer sold 18,600 shares at $20.01 ($372,186)
  17. 4 Planned sale Chief Business Officer sold 1,400 shares at $20.00 ($28,000)
  18. 3 Insider Initial Statement of Ownership
  19. 4 Planned sale Chief Business Officer sold 20,000 shares at an average $21.58 ($431,541)
  20. 4 Planned sale Chief Dev. Op. Officer sold 12,860 shares at an average $24.06 ($309,395)

Page 5 of 16 · 316 filings